Once-weekly cagrilintide–semaglutide combination therapy produced unprecedented weight reductions in adults with overweight or obesity, with 60% achieving ≥20% loss and strong cardiometabolic benefits ...

Semaglutide was associated with improved maximum walking distance across type 2 diabetes subgroups among patients with ...

A clinical trial led by an Indiana University School of Medicine researcher found that weekly doses of semaglutide - a ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt ...

Already a household name in diabetes and weight management, Ozempic (semaglutide) may soon find another surprising role — as ...

WEIGHT loss, warding off dementia, ‘curing’ diabetes and now… anti-ageing powers? Is there anything the so-called fat jabs ...

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

We have witnessed weight loss of 13–15% with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and up to 18–23% with the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...